Publication details

Quantitative detection of an IDH2 mutation for minimal residual disease monitoring in acute myeloid leukemia patients and its comparison with mutations in the NPM1 gene

Authors

JEŽÍŠKOVÁ Ivana RÁZGA Filip TOŠKOVÁ Martina DVOŘÁKOVÁ Dana TIMILSINA Shira MAYER Jiří RÁČIL Zdeněk

Year of publication 2013
Type Article in Periodical
Magazine / Source Leukemia & Lymphoma
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.3109/10428194.2012.727414
Field Oncology and hematology
Keywords PROGNOSIS; FREQUENT
Attached files
Description Acquired mutations in the IDH1 and IDH2 genes have been detected in various hematological disorders, including acute myeloid leukemia (AML), where the incidence has been reported to be 15%. The IDH1 and IDH2 genes encode enzymes that catalyze oxidative decarboxylation of isocitrate to alpha-ketoglutarate (alpha-KG). Somatic mutations cause their dysfunction and an accumulation of aberrant 2-hydroxygluterate (2-HG) product in cells. The decreased supply of alpha-KG or increased accumulation of 2-HG (i.e. metabolic biomarker of mutant IDH1/2 enzyme activity) is considered to be a possible basis for the oncogenic properties of IDH mutants.

You are running an old browser version. We recommend updating your browser to its latest version.

More info